Enovis Corporation (ENOV) Earnings

Management highlights

- Product Development and Launches * The Nebula product continues its early-stage rollout, with strong early customer conversion rates. * The Arvis 2.0 robotic surgical platform has received very positive early feedback from clinicians, particularly for its versatility, small mobile form factor, and new gap balancing technology, especially for complex shoulder anatomies. Full commercial launch is underway, with broader rollout in shoulder procedures and expansion to international markets planned for the second half of 2026. * The Recovery Sciences team is preparing to launch Revital for laser treatment in the companion animal market, which is expected to create a large new customer conversion funnel. * The company holds a strong innovation pipeline for the foot and ankle segment, which has delivered strong outperformance against market growth. - Commercial Execution * The P&R team has achieved meaningful market share gains in the regenerative medicine business following the release of proxies, demonstrating strong regional commercial execution. * The company is seeing broader account conversion across multiple segments, particularly in the fast-growing Ambulatory Surgery Center (ASC) channel, where flexible contracting creates more opportunities for share gains than locked-in contracts at large hospital systems. * The company is rolling out a shared global business services model, with existing facilities in Portugal and Hyderabad, and a third Americas facility opening soon, to drive long-term margin improvement. - Talent and Organizational Strategy * The company's stable growth and strong new product pipeline have positioned it as a talent magnet, attracting new talent from competitors over the past 12 months. * New product launches like Arvis are improving sales representative productivity, so no large-scale headcount increases are planned to hit growth goals, though the company will opportunistically add talent to drive additional account conversion.

Guidance

- The company expects a more seasonally soft Q3 than historical averages, which will act as a headwind to results. There is zero year-over-year selling day impact in Q3, and a one extra selling day impact in Q4. - The company's long-term margin and cash flow algorithm remains intact for fiscal 2027, even after the expiration of the current tariff refund benefit. Management expects to continue mitigating persistent inflation via productivity improvements and incremental adjusted cost step-downs. - The $10 million net 2026 inflation impact includes $2 million of impact realized in Q2, with the remaining $8 million expected to hit in the second half of 2026, weighted more heavily toward Q3 as mitigation efforts are implemented. - Management reaffirms the existing full-year 2025%+ free cash flow guidance and notes that Q2 free cash flow performance was slightly better than internal expectations, with a positive overall trajectory, but no upward guidance revision was made at this time. - The company remains on track to reduce its leverage ratio below 3.0 by the end of 2026, which will free up additional capacity for future M&A activity once achieved.

Segment performance

No absolute financial results or revenue contribution percentages for individual product segments are provided in the provided transcript. The Q&A section notes that the majority of the company's free cash flow continues to come from the P&R segment, while the Reconstructive (recon) segment has seen year-over-year improvement in free cash flow and delivered 6% total U.S. recon growth in the second quarter and 7% growth in the first half of 2026, outperforming broader peer group averages. The foot and ankle extremities segment grew meaningfully above the 4% to 6% market growth average in the quarter, supported by strong commercial execution.

Risks & headwinds

- Persistent inflation, exacerbated by market and competitive dynamics, particularly in the P&R segment, limits the company's ability to fully pass through cost increases to customers without risking revenue, creating a headwind for second half 2026 margins. - Proposed changes to physician payments and the ongoing CJRX regulatory process have created market noise and short-term volatility in procedure volumes. - Transient events including labor strikes, wildfires, and heat waves disrupted European market performance in Q2, and while these are expected to be temporary, there is a risk that prolonged conflict in the Middle East could shift government funding away from healthcare toward military spending, creating longer-term pressure on European procedure volumes. - Declining ACA and Medicaid enrollment in the U.S. has been cited as a concern by peer companies, though the company has not seen material changes to underlying demand dynamics from this trend to date, only increased week-to-week and month-to-month volume volatility.

Analyst Q&A

• Q: With the 2026 guidance including a tariff refund benefit that will disappear in 2027, while inflation is expected to persist, will the company's margin algorithm change for 2027? /

  A: CFO Ben stated that the 2027 margin and cash flow algorithm will not change. The company will continue to mitigate persistent inflation via productivity improvements, and expects to deliver continued incremental step-downs in adjusted costs heading into 2027, with the core long-term margin framework remaining intact.

• Q: Peers have reported disruption and weakness in the U.S. orthopedic market, partially tied to declining ACA/Medicaid enrollment. What has the company observed, and have competitor disruptions changed the competitive landscape to allow sustainable share gains? /

  A: Management said there is short-term volatility driven by policy noise, but underlying market dynamics remain stable, and the company's U.S. recon growth of 6% in Q2 and 7% H1 outperforms peers. Competitor disruptions have helped the company attract talent, and its stable growth and innovation pipeline make it an attractive destination for talent looking to grow businesses.

• Q: With Arvis's full commercial launch underway, how is adoption progressing beyond initial KOLs, and do you need additional sales headcount to support the launch? /

  A: CEO Damien McDonald reported strong positive feedback on Arvis's versatility and new gap balancing technology, with a very strong demand funnel. Rollout to shoulder procedures and international markets is planned for H2. While the company will opportunistically attract talent, Arvis improves rep productivity, so no large-scale headcount increases are required to achieve launch goals.

• Q: What is the source of the $10 million annual inflation impact, is it a gross or net number, and which segment is most affected? /

  A: CFO Ben explained the inflation impact began materializing in Q2 2026, with $2 million of impact in Q2 and the remaining $8 million expected in H2, weighted to Q3. This is a net number after existing price increases, and it impacts the P&R segment most. The company is balancing passing through costs vs. risking revenue, so it will be a minor headwind for H2 results.